Acorda Therapeutics Profit Margin

The latest profit margin for ACOR is -227.75% as of March 2024. That compares with -49.22% in the prior-year period — down 362.8% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Acorda Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACOR's profit margin moved from -49.22% to -227.75% — a 362.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acorda Therapeutics's valuation or profitability profile.

Against Healthcare companies, ACOR currently prints -227.75% for profit margin, while the sector average sits near 15.29%. That is roughly 1589.3% below the sector mean. Large gaps often invite a closer look at Acorda Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Acorda Therapeutics converts resources into returns. At -227.75%, ACOR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -49.22% in the prior-year period — down 362.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ACOR's profit margin (-227.75%), review year-over-year change from -49.22%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.